bausch report non-gaap dilut ep revenu compar
street estim respect ebitda guidanc rang
impli growth rate versu bear mind
rang reflect signific growth versu bhc advanc
pipelin topic psoriasi acn would continu interpret
someth invest year product mix continu shift away older
matur asset limit exclus runway strong visibl continu growth
xifaxan stabil global eye care busi minimum brisk line-up new
launch along limit gener exposur believ bhc well-posit
meaning long-term ebitda growth reiter overweight rate rais
pt owe modest estim revis
favor commentari xifaxan bhc note expect high-singl digit
prescript rx growth along net price improv
narrow gross-to-net commentari rx growth intuit bear mind
xifaxan rx show quarter-to-d qtd annual growth rate
versu correspond period per iqvia bhc commentari regard
rel brisk non-retail volum growth double-digit growth also intuit
bear mind sizabl portion hepat encephalopathi patient treat
institut set hospit nurs facil uncommon patient
start xifaxan treatment hospit
tidbit new launch regard vyzulta medicar part access still spotti
though bhc note half part rx cover rx
show qtd sequenti growth rate versu per iqvia regard
bryhali halobetasol psoriasi weekli rx run near per
iqvia recal bhc launch rel modest price point tube list
point refer pfizer eucrisa atop dermat list price
 tube intuit view given restrict natur
payer environ particularli brand topic agent goal bryhali
eventu duobrii rel hassle-fre patient access
aggress approach sea chang bhc think even
pend acquisit trulanc next-gener product dolcanatid
expect close later manag note still flexibl
execut addit albeit small bolt-on transact recent addit
eton over-the-count product ocular itch associ allerg
conjunct minim up-front payment said bhc make clear
synergi transact use sizabl portion deal capac
risk includ pricing/volum pressur launch risk
bausch focus rang specialti brand gener over-the-counter product
ep discount
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
summari bhc estim pjc street expect
consensu estim
compani report factset pjc estim
consensu estim
compani report factset pjc estim
page
million except per shareactualspjc lomb incom incom except per share guidanceestimatestot expens expens expens rate
consensu estim
compani report factset pjc estim
page
million except per revenuesbausch lomb tax outstand exhibit
page
fiscal year end decemb million except lomb soflen lomb oneday includ bausch lomb/ micro micro exclud ortho productswellbutrin diversifi bhc bausch health compani quarterli annual incom statement
million except ep
sale
amort
net interest
incom loss tax
expens product sale
margin total revenu
actual may slightli vari due bhc non- reconcili quarterli result estim may fulli add fy number due non- adjust individu line-item
may reflect pjc estim actual share count disclos
reflect pjc estim given bhc re-classifi revenu categori yet provid histor reconcili new segment
proprietari piper jaffray co inc februari
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
